Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2019

View Archived Issues

Low-coverage genome sequencing gives answers in infertility

Measles vaccine far more protective than realized

AGTC announces second ophthalmology program, reports promising preclinical data on dual AAV

CD205-targeting antibody-drug conjugate shows selective antitumor efficacy in preclinical studies

FDA clears IND application for phase II study of VB-111 in surgically accessible rGBM

Hoth Therapeutics initiates confirmatory study of the AEA-loaded-Z pods in models of lupus

New milestones announced for hematology product candidate AXA-4010

Phase III study of Treakisym in DLBCL achieves primary endpoint of ORR

Vaccibody announces preliminary phase I/IIa data for VB10.NEO neoantigen cancer vaccine

Early clinical data presented for AGIL-AADC gene therapy in children with AADC deficiency

Adagene presents first-in-human data for ADG-106

ABSK-041, a highly potent and orally available small-molecule PD-L1 antagonist

Sanofi Pasteur presents preclinical data for ZIKV vaccine ZPIV-SP

Schizophrenia biomarker can be detected in human hair

Boehringer Ingelheim reports data on new SOS1-KRAS interaction inhibitors for cancer

New phase I trial explores BI-1701963 in KRAS-mutated advanced or metastatic solid tumors

Retrotope initiates phase II/III study of RT-001 in Friedreich's ataxia

Lilly opens phase I study of LY-3435151 in advanced solid tumors

Bristol-Myers Squibb presents new MGAT2 inhibitors

U.K. researchers patent BCL-6 inhibitors

Thomas Helledays Stiftelse foer Medicinsk Forskning divulges MTHFD2 inhibitors

VTCN1 gene linked to schizophrenia in Chinese families

Chinese researchers present new p300 HAT inhibitors

Hungarian scientists patent myosin-2 ATPase activity inhibitors

ObsEva to discontinue nolasiban IVF program after phase III trial misses primary endpoint

CARB-X grant supports Techulon's development of new class of antimicrobial

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...